ALFA Finder| Revenue growth | ₹736cr in Q4 (+22% QoQ); ₹2,542cr for FY26 (-1% YoY). |
|---|---|
| Margins | EBITDA margin normalized at 23% in Q4; guidance to maintain this range. |
| Demand visibility | Positive India demand; recovery in CPVC and caustic soda utilization. |
| Management confidence | Confident in FY27 volume growth of 10-12% post-maintenance. |
Growth
Q4 revenue grew 22% QoQ to ₹736cr; FY26 revenue dropped 1% to ₹2,542cr due to H1 volume de-growth.
Outlook
Targeting 10-12% volume growth in FY27; CPVC/ECH capacity doubling expected by Q2FY27; 90-95% captive chlorine consumption targeted.
Risks
West Asia conflict disrupting supply chains, inflationary raw material costs, and potential monsoon-related demand volatility.
Earnings Call filed with NSE, NSE: EPIGRAL. Summary written with AI assistance from the document.
Epigral Ltd: key numbers
- Share price
- ₹942.55
- Market cap
- ₹4,066 Cr
- Revenue (annual)
- ₹2,527 Cr
- Net profit (annual)
- ₹332.0 Cr
- P/E (TTM)
- 14.3×Sector 35.5×
- Promoter holding
- 68.83%+0.00% QoQ
- FII holding
- 0.99%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Epigral Ltd
All →Epigral Earnings Call Transcript: Key Takeaways
Q2 FY27 revenue up 28% and PAT up 26%, but EBITDA rose only 3% as margin fell to 18%. Management's FY27 outlook is qualitative; no growth number was given.
Epigral Investor Presentation: Key Takeaways
Q2FY27 revenue ₹752 Cr (+28% YoY) and PAT ₹64 Cr (+26%). EBITDA margin fell to 18% (23% YoY) on raw material costs. Derivatives & Specialty now 57% of revenue. CPVC and ECH capacity due Q3FY27.
Epigral Results Update
Epigral reported Q2 FY27 PAT of ₹64 Cr, up 26% YoY, with revenue at ₹752 Cr. EBITDA margin was 18% despite elevated raw material costs.
Epigral Q2 FY27 Results: Net Profit ₹65.1 Cr, Up 27.1% YoY
Epigral Ltd reported revenue from operations of ₹746 Cr (+27.0% YoY) and net profit of ₹65.1 Cr (+27.1% YoY) for Q2 FY27.
- Key figure
- Net profit ₹65.1 Cr · +27.1% YoY
Epigral Credit Rating
CRISIL revised Epigral's ratings to CRISIL AA/Stable (long-term) and CRISIL A1+ (short-term) on its bank facilities. The action covers Rs.1,050 Crore of rated bank loan facilities.
Epigral Legal & Regulatory
Epigral received a Rs.28.11 crore income tax demand for AY 2023-24, including interest. The company considers the demand unmaintainable and is filing an appeal.
- Value
- ₹28.11 Cr